kl chart 2024 result Nanoparticles help CRISPR knockout of oncogenes significantly increase tumor delivery Taiji Group disrupts the 1.5 billion injection market and "challenges" original research ...

Jim Cramer, the host of Mad Money, recently shared some investment guidelines based on his 40 years of experience.

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Eli Lilly's recent breakthroughs and its promising pipeline should help drive excellent financial results for a long time.

The Carroll County Community Foundation is pleased to announce the recipient of the 2025 Lilly Endowment Community ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...

AHA shares feedback in response to the Centers for Medicare & Medicaid Services’ information collection request (ICR) regarding the Medicare Transaction Facilitator (MTF) and the Medicare drug ...

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...